Shares of Immunome Inc. IMNM,
blew 212.6% higher on Thursday to new highs, accelerating all pre-sellers trading on the major US stock market, after the biopharmaceutical company said it had isolated strong antibodies that could neutralize several SARS-CoV-2 variants , including the South African Variant (B.1.351) in pseudovirus testing. The trading volume was approximately 506,600 shares, compared to the average day of approximately 117,600 shares. The company is working to develop a cocktail of antibodies (IMM-BCP-001) that can serve as a treatment for COVID-19. “Our findings highlight the power of Immunome’s discovery engine to quickly identify antibodies that are broadly effective against SARS-CoV-2 and its variants,” said Purnanand Sarma, chief executive. “We are encouraged by these results and plan to continue developing these antibodies.” The stock, which was announced on October 2, 2020, has risen 129.6% to date, while the iShares Nasdaq Biotechnology ETF IBB,
advanced by 10.6% and the S&P 500 SPX,
achieved 4.7%.
